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Polyomavirus BK-associated nephropathy (PyVAN) is the main infectious cause of allograft damage after kidney transplantation.
A number of studies revealed an association between the presence of BKV-specific cellular immunity and BK viral clearance, with
patients failing to recover specific T cells progressing to PyVAN. Evolution to allograft dysfunction can be prevented by restoration
of BKV-specific immunity through a stepwise reduction of maintenance immunosuppressive drugs. Prospective monitoring of BK
viral load and specific immunity, together with B-cell alloimmune surveillance, may allow a targeted modification/reduction of
immunosuppression, with the aim of obtaining viral clearance while preventing graft injury due to deposition of de novo donor-
specific HLA antibodies and late/chronic antibody-mediated allograft injury. Innovative, immune-based therapies may further
contribute to BKV infection prevention and control.
1. Introduction
The morbidity and mortality of viral infections are signifi-
cantly increasing in transplant patients. The reason resides in
the severe impairment in immune surveillance caused by the
development of potent induction andmaintenance immuno-
suppressive protocols, which has led to a significant amelio-
ration of graft outcome but, on the other hand, has weakened
protective immune functions against pathogens [1]. System-
atic immune control is needed in order to restrict the rate and
level of latent virus reactivation since, by definition, clearance
from the host cannot be obtained for such viruses, regardless
of the antiviral treatment.
Polyomavirus BK (BKV), first isolated in the 1970s, is a
double-stranded DNA virus with a genome structure con-
sisting of the early nonstructural genes encoding large T and
small t antigens, the late genes encoding the capsid proteins
(VP1, VP2, and VP3) and the agnoprotein and a noncoding
control region (NCCR) harboring viral promoters and the
origin of replication [2]. BKV seroprevalence exceeds 90% in
the adult population worldwide, but the infection does not
cause illness in healthy individuals [3]. Prevalence and level
of BKV replication in urine, occasionally observed in healthy
individuals [4], may increase with pregnancy, kidney disease,
and immunodeficiency status including hematopoietic stem
cell and renal transplantation [2]. In the latter setting, BKV
has emerged in the last 15 years as the most challenging
infectious cause of renal allograft dysfunction and graft loss
[5]. BKV-related nephropathy (PyVAN)was initially reported
to cause graft loss in 10% to >80% of cases [5–8], but
implementation of BKV monitoring strategies after trans-
plantation and prompt/preemptive therapeutic intervention
had a positive impact on graft outcome [6, 9, 10].
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In association with viral load determination, quantifica-
tion of the specific immune response has gained considera-
tion as a useful tool in the management of viral infections
in the immunocompromised host. In detail, viral immunity
monitoring has allowed the characterization of subgroups of
patients at high risk for disease development [11] and assess-
ment of response to antiviral therapy [12]. In addition, as
control of infection depends on the restoration of a protective
immune response, characterization of specific viral immunity
has facilitated development of recombinant or cellular vac-
cines [13–15].
Here, we will review available evidence on BKV-specific
immune responses, suggest an immunological monitoring
approach to the management of BKV reactivation and
PyVAN, anddiscuss possible future immune-based therapeu-
tic options.
2. Diagnosis and Monitoring of BK Infection
PyVAN diagnosis is made by renal biopsy, with evidence of
polyomavirus cytopathic changes and interstitial nephritis
[5, 9, 10, 16], but the focal nature of the disease and the
possible overlap with other pathologies that complicate the
posttransplant course couldmake difficult an early diagnosis.
PyVAN represents a complication linked to high-rate
virus replication in the grafted kidney [2, 17]. Thus, monitor-
ing of BK viruria, generally by urine cytology or quantitative
PCR for viral DNA, and monitoring of BK viremia, by
quantitative PCR, allow the identification of patients at risk
of developing PyVAN [5, 9, 10]. Urine and plasma seem
to be separate replication compartments, with plasma being
directly linked to graft replication [18]. Consequently, sus-
tained detection of BKV replication, assessed as plasma loads
by quantitative PCR, is the most predictive assay for the
presence of “presumptive” PyVAN [2, 5, 17], and for this
reason, it is recommended by current guidelines as the best
assay to guide preemptive interventions [5, 9, 10, 19–21].
In association with viral molecular monitoring, analysis
of specific immune responses could become instrumental in
assisting the surveillance and treatment of kidney recipients
with BKV replication and PyVAN [22, 23]. However, in order
to reach this aim, assessment of the most cost-effective
immunemonitoring protocol together with development and
standardization of “high throughput” assays is needed [24].
3. Immune Responses in Patients with
BK Infection and Disease
To introduce a proposal for a protocol of specific immune
monitoring to be employed in patients with BKV replication
or PyVAN, we shall give a preliminary overview of humoral
and cellular immunity in patients with active BKV infection
and disease.
3.1. Innate Immune Responses. The host immune response is
of central importance in limiting primary viral infection and
in controlling the virus carrier state. In general, the first line
of defense against infection, prior to increase in antibody
titers and epitope-specific HLA-restricted T-cell populations,
is under control of innate responses and nonspecific cytotoxic
cells (natural killer cells, lymphokine-activated cells, and
MHC-unrestricted 𝛾𝛿+ T-lymphocytes). One study demon-
strated an association between lack of the HLA-C7 allele
and sustained BK viremia [25], indirectly suggesting a role
for inhibitory and activating killer-cell immunoglobulin-like
receptors (KIRs) in the control of BKV infection. However,
KIR genotyping studies, which had demonstrated a role for
activating KIRs in the control of CMV infection in both
hematopoietic stem cell and kidney transplantation [26, 27],
ruled out an effect of KIR genotype on the rate of BKV
reactivation [27].
Innate immunity may also have a detrimental role in
BKV-related disease. A recent report demonstrated in biop-
sieswith PyVAN that the activation of innate immunedefense
mechanisms, especially via TLR3, is implicated in the anti-
viral and inflammatory response [28].
3.2. Humoral Immune Responses. Humoral immunity still
has a controversial role in the regulation of BKV activity.
BKV-specific antibodies are present in 82% of individuals [4].
Studies conducted in pediatric kidney transplant recipients
have shown that BKV seronegativity correlates with a higher
risk of BKV replication and PyVAN [29, 30]. However, clin-
ical observations indicate that having experienced a humoral
response does not give full protection from post-transplant
reactivation of viral replication and development of poly-
omavirus-related disease [5, 20].
In cohorts of kidney transplant recipients experiencing
high-levels of viruria or viremia, compared to patients with-
out active viral replication, the course of BKV-specific anti-
body responses has been shown to follow the level and
duration of BKV replication [20, 25, 31, 32].
3.3. Cellular Immune Responses. The coincidence of PyVAN
with the widespread clinical application of potent triple
immunosuppressive regimens suggests a role for marked
cellular immunodeficiency in disease progression. Likewise,
one study showed that pretransplant dendritic cell defi-
ciency, leading to diminished antigen presentation and T-
cell activation, correlated with a high risk of posttransplant
BKV viremia and progression to PyVAN [33]. Early studies
demonstrated that control of BKV replication and PyVAN in
kidney recipients correlated with emergence of BKV-specific
cellular immune responses [34, 35]. Moreover, a longitudinal
analysis showed that kidney recipients with BKV reactivation
had undetectable levels of BKV-specific IFN-𝛾 secreting cells.
Upon immunosuppression reduction, while BKV loads in
plasma and urine declined, an increase in the frequency of
virus-specific T cells was observed, which coincided with
reduction of serum creatinine levels, an index of allograft
function stabilization [20]. A recent study confirmed that
patients with self-limited BKV reactivation were those who
rapidly developed BKV-specific T cells without therapeutic
interventions [36].
The cellular response pattern to BKV antigens has been
an object of study. Results obtained in healthy individuals
and in kidney transplant recipients revealed responses to
BKV large T, small t, VP1, VP2, and VP3 proteins, but no
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immunodominant antigen was identified [37, 38]. Analyzing
cases of resolved PyVAN/past BK viremia or patients with
transient/no BKV infection, two independent groups found
higher frequencies of IFN-𝛾 producing T cells directed to
viral capsid antigens, respectively, VP1 andVP3, in the former
group [20, 35, 39, 40]. In conclusion, although recent studies
confirmed that lymphocytes directed to all five BKV pro-
teins are potentially inducible [15, 38–40], the magnitude
of the capsid protein-specific pool is highest. Conversely,
Leuenberger et al. demonstrated that agnoprotein is immu-
nologically ignored [41]. Cioni et al. have recently investi-
gatedwhether agnoproteinmight contribute to BKV immune
evasion by interfering with HLA surface expression or pep-
tide presentation and found that no HLA-ABC or DR down-
regulation, as well as no interference with peptide-dependent
cytotoxicity, was mediated by the agnoprotein [42].
Although data are available on the distribution and
immunodominance of responses to BKV proteins, there is
limited evidence on their respective role in the containment
of BKV replication and progression to disease. In this regard,
Comoli et al. [43] have shown in a prospective study that
the presence of large T antigen-specific, but not VP1-specific,
cytotoxic T cells at an early time after transplantation protects
from the risk of BK viruria and that in patients with viruria,
the emergence of BKV LT antigen-specific immunity is
associated with protection from development of BK viremia.
Though several studies focused on BKV-specific cell
immunity, it remains unclear whether BKV responses are
mediated preferentially by CD4+ or CD8+ T-lymphocytes,
and in particular which subset plays a protective role in the
control of the infection [20, 35, 38–40]. It was shown that in
kidney transplant patients with active or past BKV replication
VP1-specific IFN-𝛾-producing T cells were preferentially
CD4+, whereas the CD8+ population was predominantly
large T specific [35]. In agreement with these observations, it
was shown that BKV seropositive donors mount a powerful
CTL response towards epitopes encompassed by a highly
phylogenetically conserved region of the LTag implicated in
viral replicative activity and in the p53-mediated control of
the cell cycle of host cells [44], and BKV-directed cytotoxic
activity in kidney recipients after viral clearance was mostly
directed against LT antigen [20]. On the other hand, themag-
nitude of memory multifunctional CD4+ T cells was found
to correlate with the severity of the previous BKV infection
[40], and a higher frequency of BKV large T-specific CD4+
cells characterized by a cytotoxic profile (secretion of TNF-
𝛼, IFN-𝛾, and presence of Granzyme A and B) was shown
in healthy individuals [38]. Although this issue needs to be
further investigated, there is preliminary evidence suggesting
that CD4+ T-lymphocytes could play an essential role not
only in providing helper functions but also as effectors able
to exert direct control of virus replication [29].
4. Management of BKV Reactivation, PyVAN,
and the Risk of Antibody-Mediated Graft
Damage: The Role of Immune Monitoring
No specific antiviral therapy has, so far, proven effective in
containing PyVAN and preventing allograft damage [45, 46].
However, a number of studies have shown that progression
to PyVAN can be safely prevented if BKV viremia is used to
guide therapeutic intervention [17, 19, 20].
BKV replication is generally an early event after allo-
grafting, and therapeutic reduction of immunosuppressive
agents in this crucial phase of transplantation may induce
acute rejection episodes, or, worse, affect long-term allograft
outcome. Indeed, in a study of PyVAN surveillance and pre-
emptive therapy, for adult kidney recipients with BK viremia
treated with concomitant reduction of calcineurin inhibitors
(CI) and mycophenolate mofetil (MMF), an acute rejection
incidence of 13% was observed after modulation of immuno-
suppression [21]. Moreover, in the cohort treated with step-
wise reduction of immunosuppression by Brennan et al. [19],
despite the low acute rejection rate, a significantly worse graft
outcome for BK viremic patients was observed at long-term
followup [47].
Late/chronic active antibodymediated rejection (CAMR)
has emerged as an important cause of late kidney transplant
failure [48]. Lately, development of de novo donor-specific
HLA antibodies (DSA) was found to be associated with
CAMR and poor graft outcome in adult and pediatric cohorts
of kidney recipients at low immunological risk [49, 50]. In
a low-risk pediatric population on conventional CNI-based
triple drug regimen, development of de novo DSA occurs in
almost a fourth of the patients [50]. It has been hypothesized
that a potentially self-limiting and transient broad pan-B cell
activation, due to non-specific stimuli [51], or to low-level
allo-specific T-cell help to B-cells promoted by the loss of
induction therapy effect and by protocol decrease in main-
tenance immunosuppression, may, under particular clinical
conditions, such as molecular mimicry elicited by viral reac-
tivation [52], be amplified and lead to the emergence of DSA
[50]. In this scenario, BKV reactivation could represent both
a trigger for B cell activation, and, through specific thera-
peutic reduction of immunosuppression, sustainment ofDSA
formation.
In the setting thus delineated, detection of BKV-specific T
cells by immunemonitoring represents a unique tool to allow
for a cautious modulation of immune suppression, with the
ultimate goal of controlling viral reactivationwhilemaintain-
ing adequate immune suppression to protect the graft [24].
Indeed, we have evidence that as soon as virus-specific T-
cell responses appear, the patient acquires protection from
PyVAN progression [20]. Thus, we propose a combined
immune surveillance approach: throughDSAmonitoring, we
could identify viremic patients at potential risk of CAMR
secondary to immunosuppression reduction, while BKV
cellular immunity monitoring could tell us in which of these
patients wemay safely consider restoring part of the preinfec-
tion maintenance immunosuppression.
5. A Launch into the Future: Innovative
Immune-Based Therapeutic Strategies to
Control Polyomavirus Infection and
Prevent Related Disease
As several reports have demonstrated that an efficient
BKV-specific T-cell response is crucial for control of viral
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replication and prevention of progression to PyVAN, the
development of alternative therapeutic approaches aiming
to restore an effective viral-specific immune response, is an
attractive alternative to current treatment options [15, 20, 34–
40].
Antiviral cell therapy strategies, at first successfully
employed in the setting of hematopoietic stem cell trans-
plantation [53, 54], have subsequently been transferred to the
setting of organ transplantation [55, 56]. Our group described
amethod for the generation of BKV-specificCTLs fromBKV-
seropositive healthy donors and kidney transplant patients,
based on the stimulation of PBMCwith dendritic cells pulsed
with inactivated BKV, in the presence of IL-7 and IL-12 [57].
As result, it was possible to obtain BKV-specific T cells
with cytotoxic activity. In particular, a high frequency of
CD3+/TCR𝛾𝛿+ cells was observed, displaying an MHC-
unrestricted cytotoxicity and suggesting a protective role in
the control of the virus from the graft [9].
The use of BKV protein peptide mixtures as the antigen
stimulus would permit good manufacturing practice (GMP)
generation of T-cell lines with multiple specificities to be
used for patients of any HLA type. Recently, Blyth et al. [14]
generated BKV-specific T cells for possible use in adoptive
cell transfer by antigenic stimulation with 15mer peptide
pools derived from VP-1, VP-2, VP-3, small t, and large T
antigens. As the frequency of T cells specific for BKV was
rather low when compared to other persistent viruses, 15mer
peptides may not be an optimal antigen for T-cell generation.
Unfortunately, HLA-restricted T-cell response to BKV is so
far poorly characterized and only few VP-1 and large T anti-
gen epitopes have been defined, with most of the described
epitopes beingHLAA∗02 restricted [38, 44, 58–61]. Recently,
a large T antigen-derived peptide has been described that
seems to elicit a CD4+ T-cell response across different HLA
types [62].
No clinical trial has so far been published on adoptive
BKV-specificT-cell transfer.However, our groupwas success-
ful in treating anHSCT recipient affected by progressivemul-
tifocal leukoencephalopathy with polyomavirus JC-specific T
cells obtained by stimulating PBMCs from the HSCT donor
with a pool of 15mer peptides spanning the whole sequence
of JCV VP-1 and the large T antigen [63]. A similar strategy
could be employed in case of JC-mediated PyVAN [64] and
be translated to the treatment of BK PyVAN.
Finding immunodominant peptides would be of interest
also in the context of vaccine development. As peptide vac-
cination is generally a poor inducer of cellular immunity, the
use of carrier adjuvants may be necessary. Virus-like particles
(VLPs) are optimal carrieres for antigen delivery. Murine
polyomavirus VLPs were tested in mice and found to induce
a strong humoral and cellular immune response [65]. An
infectious recombinant BK virus, in which the large T seq-
uence could be modified to avoid any safety implication
related to the potential tumorigenicity of large T antigen, was
recently proposed as an alternative strategy for vaccination in
the context of BKV [66].
6. Conclusions
Successful clearance of BK viremia and prevention of PyVAN
after kidney transplantation rely on the efficiency of the
immune system and,more precisely, specific T-cell immunity.
Reduction of maintenance immunosuppression is able to
restore protective immunity, but recent evidence indicates
how immune suppression modulation needs to be carefully
balanced against the risk of inducing de novo DSA and
CAMR.
Combined monitoring of DSA and BKV-specific T cells
could provide an easy and safe tool for the therapeutic man-
agement of kidney recipients developing BKV reactivation.
Novel immune-based strategies, including vaccination and
cell therapy, might further contribute to the prevention of
BKV infection and related disease.
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